Introduction & Objective: The Asian-Indian phenotype presents with increased insulin resistance, reduced Beta-Cell function, abdominal adiposity & clustering of CV risk factors. In India generic DPP4i/SGLT2i Fixed Drug Combinations (FDCs) are prescribed to enhance compliance amongst patients with T2DM. We aimed to study attitude & practice of Indian Physicians pertaining to patient populations benefitting from these FDCs.

Methods: We designed and utilized a 6-question survey during an Indian Medical Congress. Convenience Sampling was used to reach out to at least n=150 physicians. Descriptive Statistics was used to analyze data using MS-Excel 2019.

Results: Amongst 185 surveyed physicians, 48% respondents (n=89) reported over 40% of newly-diagnosed, treatment-naïve patients presenting with baseline HbA1c >8%. 52% (n=97) had more than 40% patients with HbA1c >8.5% despite Metformin monotherapy. Considering glycemic control in 3 clinical scenarios, 66% (n=122) physicians preferred DPP4i/SGLT2i FDCs for all scenarios namely (a) patients uncontrolled on Metformin monotherapy with HbA1c >8.5% (b) treatment-naive patients with contraindication/intolerance to Metformin & HbA1c >8% (c) add-on to insulin. Also 60.5% (n=112) physicians favored DPP4i/SGLT2i FDC for all 4 given reasons i.e. CV benefits, lower hypoglycemia risk, weight loss promotion & targeting multiple pathophysiological pathways. 85% (n=158) reported reduced Genito-Urinary Tract Infections (GUTI) with concurrent administration of DPP4i with SGLT2i or FDC. Most favored FDC was Sitagliptin/Dapagliflozin (36%, n=67).

Conclusion: In India there is significant burden of patients with T2DM who present with high HbA1c (newly diagnosed or despite metformin monotherapy). Generic DPP4i/SGLT2i FDCs are preferred in these patients also considering their extra-glycemic benefits. Most physicians (85%) noted reduction in SGLT2i associated GUTIs with use of DPP4i/SGLT2i FDCs. Further studies may validate these findings.

Disclosure

B. Saboo: None. C.M. Prajapati: Employee; Macleods Pharmaceuticals Ltd. P.A. Shetty: Employee; Macleods Pharmaceuticals Ltd., Eisai Inc. P. Muralidharan: Employee; Macleods Pharmaceuticals. A. Qamra: Employee; Macleods Pharmaceuticals Ltd.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.